SEC Form 4 · accession 0001485003-18-000003
Sesen Bio, Inc. · SESN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen A Hurly
Officer — President and CEO · Director
Period of report
Jan 18, 2018
Accepted (ET)
Jan 22, 2018 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001485003
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $1.59 | Jan 18, 2018 | A | 80,430 | A | Jan 18, 2018 | Oct 3, 2027 | Common Stock | 80,430 | 80,430 | D |
Explanation of responses
- F1On October 4, 2017, the reporting person was granted an option to purchase 420,000 shares of common stock. This option vests in installments based on the achievement of certain strategic and clinical milestones. On January 18th, 2018, the Compensation Committee of the Board of Directors of the Company determined that one of these performance milestones was met, resulting in vesting of the option with respect to 80,430 shares.